- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03958734
Postprandial Monocyte Maturation and Vascular Dysfunction Following High-Fat Meals - Study 1
April 11, 2022 updated by: Virginia Commonwealth University
Postprandial Monocyte Maturation and Vascular Dysfunction Following High-Fat Meals: The Impact of Cardiovascular Fitness and Acute Aerobic Exercise - Study 1
The purpose of this research study is to examine the effect of high-fat meals on the health of blood vessels.
In addition, the study will examine how exercise/fitness/physical activity impacts blood vessels after consumption of a high-fat meal.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is the first in a series of studies examining the impact of high-fat meals on blood vessels.
During the preliminary visit of this study, eligible participants' resting metabolic rate, arm flow mediated dilation, and leg flow mediate dilation will be measured.
They will complete handgrip and plantar flexion exercise tasks.
Finally, they will be given a physical activity monitor to wear for 7 days.
At their first visit, participants will eat a high-fat meal and blood will be drawn to measure blood vessel health.
They will also repeat the arm flow mediated dilation, leg flow mediate dilation, handgrip, and plantar flexion exercise tests.
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 30 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- college-age: 18-30 years old
- normal fasting triglyceride (<150 mg/dL) (American College of Sports Medicine Guidelines for Exercise Testing and Prescription, 10th Edition).
- normal body composition: % body fat, males <25%, females <32% (American College of Sports Medicine Guidelines for Exercise Testing and Prescription, 10th Edition)
- self-reported engagement in moderate-vigorous intensity physical activity and/or an exercise training regimen OR self-reported low physical activity and no engagement in an exercise training regimen (International Physical Activity Questionnaire)
- low cardiorespiratory fitness (VO2peak; male: =<45 mL/kg/min; female: =<35 mL/kg/min; categorized as =40th percentile by ACSM Guidelines for Exercise Testing and Prescription, 10th Edition; 44, 45, 46, 47) OR high cardiorespiratory fitness (VO2peak; male: =55 mL/kg/min; female: 45 mL/kg/min; categorized as =70th percentile by ACSM Guidelines for Exercise Testing and Prescription, 10th Edition; 44, 45, 46, 47)
f.) for female participants, presence of a normal, monthly menstrual cycle with or without prescribed contraceptive methods.
.
Exclusion Criteria:
- presence of diagnosed cardiovascular, metabolic, or renal disease or dysfunction
- presence of signs and symptoms suggestive of cardiovascular, metabolic, or renal disease
- presence of musculoskeletal injury
- pregnancy
- history of smoking
- engagement in an abnormal eating behavior
- unable to communicate effectively in English
- moderate cardiorespiratory fitness (VO2peak; male: 46-54 mL/kg/min; female: 36-44 mL/kg/min)
- elevated or high fasting triglycerides (>150 mg/dL)
- absence of a normal, monthly menstrual cycle with or without prescribed contraceptive methods
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: Low physical activity/fitness
Participants will be classified as into low-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
|
Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
|
|
OTHER: High physical activity/fitness
Participants will be classified as into high-physical fitness based on self-reported physical activity and cardiorespiratory fitness testing.
|
Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting triglycerides
Time Frame: Baseline
|
Ester derived from glycerol and three fatty acids, representative of the main constituent of body fat in humans.
|
Baseline
|
|
Post HFM Triglycerides
Time Frame: 4 hours
|
Ester derived from glycerol and three fatty acids, representative of the main constituent of body fat in humans.
|
4 hours
|
|
Fasting total cholesterol
Time Frame: Baseline
|
Type of lipid that is required for cell structure, but can contribute to increased risk of heart disease if high due to development of fatty deposits on vascular wall.
|
Baseline
|
|
Post HFM total cholesterol
Time Frame: 4 hours
|
Type of lipid that is required for cell structure, but can contribute to increased risk of heart disease if high due to development of fatty deposits on vascular wall.
|
4 hours
|
|
Fasting LDL
Time Frame: Baseline
|
Low density lipoprotein that transports fat molecules in the body.
Associated with high levels of cholesterol.
|
Baseline
|
|
Post HFM LDL
Time Frame: 4 hours
|
Low density lipoprotein that transports fat molecules in the body.
Associated with high levels of cholesterol.
|
4 hours
|
|
Fasting HDL
Time Frame: Baseline
|
High density lipoprotein that transports fat molecules in the body.
Associated with carrying cholesterol to the liver for degradation.
|
Baseline
|
|
Post HFM HDL
Time Frame: 4 hours
|
High density lipoprotein that transports fat molecules in the body.
Associated with carrying cholesterol to the liver for degradation.
|
4 hours
|
|
Fasting non-HDL
Time Frame: Baseline
|
Total cholesterol minus HDL, often associated with a better assessment of risk for heart disease.
|
Baseline
|
|
Post HFM non-HDL
Time Frame: 4 hours
|
Total cholesterol minus HDL, often associated with a better assessment of risk for heart disease.
|
4 hours
|
|
Fasting LDL/HDL ratio
Time Frame: Baseline
|
Assessment of risk for heart disease.
|
Baseline
|
|
Post HFM LDL/HDL ratio
Time Frame: 4 hours
|
Assessment of risk for heart disease.
|
4 hours
|
|
Fasting anti-inflammatory surface receptor expression
Time Frame: Baseline
|
CD14, CD206 - monocyte receptors associated with defining subsets and inflammatory differentiation of macrophages.
|
Baseline
|
|
Post HFM anti-inflammatory surface receptor expression
Time Frame: 4 hours
|
CD14, CD206 - monocyte receptors associated with defining subsets and inflammatory differentiation of macrophages.
|
4 hours
|
|
Fasting pro-inflammatory surface receptor expression
Time Frame: Baseline
|
CD16, CD86 - monocyte receptors associated with defining subsets and inflammatory differentiation of macrophages.
|
Baseline
|
|
Post HFM pro-inflammatory surface receptor expression
Time Frame: 4 hours
|
CD16, CD86 - monocyte receptors associated with defining subsets and inflammatory differentiation of macrophages.
|
4 hours
|
|
Fasting brachial artery flow-mediated dilation
Time Frame: Baseline
|
Dilation of brachial artery when blood flow increases in artery.
Measured by non-invasive ultrasound.
|
Baseline
|
|
Post HFM brachial artery flow-mediated dilation
Time Frame: 5.5 hours
|
Dilation of brachial artery when blood flow increases in artery.
Measured by non-invasive ultrasound.
|
5.5 hours
|
|
Fasting superficial artery flow-mediated dilation
Time Frame: Baseline
|
Dilation of superficial artery when blood flow increases in artery.
Measured by non-invasive ultrasound.
|
Baseline
|
|
Post HFM superficial artery flow-mediated dilation
Time Frame: 5.5 hours
|
Dilation of superficial artery when blood flow increases in artery.
Measured by non-invasive ultrasound.
|
5.5 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert L Franco, PhD, Virginia Commonwealth University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 17, 2019
Primary Completion (ACTUAL)
April 29, 2021
Study Completion (ACTUAL)
April 29, 2021
Study Registration Dates
First Submitted
May 17, 2019
First Submitted That Met QC Criteria
May 17, 2019
First Posted (ACTUAL)
May 22, 2019
Study Record Updates
Last Update Posted (ACTUAL)
April 13, 2022
Last Update Submitted That Met QC Criteria
April 11, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM20015510-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipemia
-
University of GuelphCompletedSatiety | Postprandial LipemiaCanada
-
Malaysia Palm Oil BoardNational University of Malaysia; Taylor's UniversityCompletedGastric Emptying | Postprandial Lipemia | Postprandial GlycemiaMalaysia
-
National Taiwan Sport UniversityCompletedPostprandial Lipemia | Time-restricted FeedingTaiwan
-
University of GuelphRecruitingPostprandial Lipemia | Postprandial Glycemia | Satiation, SatietyCanada
-
National Taiwan Sport UniversityCompletedLipemia | Nutritional and Metabolic DiseasesTaiwan
-
Aarhus University HospitalArla Foods; The Danish Obesity Research Centre; Nordic Centre of ExcellenceCompletedType 2 Diabetes | Postprandial LipemiaDenmark
-
University of JordanCompleted
-
Federico II UniversityCompleted
-
Maastricht University Medical CenterRecruitingGlucose Metabolism | Abdominal Obesity | Lipid Metabolism | Postprandial LipemiaNetherlands
-
Iowa State UniversityCompleted
Clinical Trials on High-fat meal
-
USDA, Western Human Nutrition Research CenterTerminatedObesity | Overweight | Body WeightUnited States
-
Agroscope Liebefeld-Posieux Research Station ALPCompletedObesity | Nutritional InterventionSwitzerland
-
Pennington Biomedical Research CenterCompletedDiabetes Mellitus, Type 2United States
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
Universidad IcesiUniversidad de San BuenaventuraCompletedCardiovascular DiseasesColombia
-
Ball State UniversityRecruiting
-
Instituto de Investigacion Sanitaria La FeHospital Universitario La Fe; Universitat Politècnica de ValènciaNot yet recruitingType 1 Diabetes Mellitus | Menstrual Cycle | Dietary Fat | Glycemic Variability | Postprandial Glucose | Sex CharacteristicsSpain
-
Wageningen UniversityTop Institute Food and NutritionCompletedCardiovascular Disease | Endothelial DysfunctionNetherlands
-
University of ReadingUnilever R&DCompletedCardiovascular DiseaseUnited Kingdom
-
Boehringer IngelheimCompleted